A detailed history of Jfs Wealth Advisors, LLC transactions in Genmab A/S stock. As of the latest transaction made, Jfs Wealth Advisors, LLC holds 82 shares of GMAB stock, worth $1,688. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82
Previous 141 41.84%
Holding current value
$1,688
Previous $3,000 66.67%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$23.84 - $28.48 $1,406 - $1,680
-59 Reduced 41.84%
82 $1,000
Q2 2024

Jul 15, 2024

BUY
$25.13 - $30.27 $527 - $635
21 Added 17.5%
141 $3,000
Q1 2024

Apr 30, 2024

SELL
$26.43 - $32.77 $3,277 - $4,063
-124 Reduced 50.82%
120 $3,000
Q4 2023

Feb 07, 2024

BUY
$27.94 - $35.44 $1,564 - $1,984
56 Added 29.79%
244 $7,000
Q1 2023

Apr 19, 2023

SELL
$34.88 - $43.22 $2,336 - $2,895
-67 Reduced 26.27%
188 $7,000
Q4 2022

Feb 13, 2023

SELL
$33.8 - $47.06 $236 - $329
-7 Reduced 2.67%
255 $10,000
Q3 2022

Oct 21, 2022

BUY
$31.52 - $373.61 $7,533 - $89,292
239 Added 1039.13%
262 $8,000
Q2 2022

Aug 02, 2022

SELL
$26.83 - $38.57 $4,051 - $5,824
-151 Reduced 86.78%
23 $1,000
Q1 2022

May 02, 2022

BUY
$30.95 - $39.68 $3,992 - $5,118
129 Added 286.67%
174 $6,000
Q4 2021

Feb 03, 2022

SELL
$35.87 - $47.12 $2,223 - $2,921
-62 Reduced 57.94%
45 $2,000
Q3 2021

Nov 09, 2021

BUY
$41.55 - $48.72 $4,445 - $5,213
107 New
107 $5,000
Q2 2020

Aug 05, 2020

SELL
$20.05 - $33.89 $2,005 - $3,389
-100 Closed
0 $0
Q1 2020

Apr 29, 2020

SELL
$17.15 - $25.22 $15,434 - $22,698
-900 Reduced 90.0%
100 $2,000
Q3 2019

Oct 31, 2019

BUY
$18.0 - $21.38 $18,000 - $21,380
1,000 New
1,000 $20,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.6B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Jfs Wealth Advisors, LLC Portfolio

Follow Jfs Wealth Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jfs Wealth Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jfs Wealth Advisors, LLC with notifications on news.